“Bill Hahne and I worked together at Curagen. I was the pharmacologist responsible for the preclinical development of several of our projects in the company while he led our clinical development team. His role leading the clinical effort was critical in shaping how the preclinical work took place. We worked as a team to carefully tailor the work that would then become part of the regulatory submissions. With his guidance our research efforts were clearly translatable into the clinical candidates we were developing. His clinical insight is nicely backed up with his scientific training; making him a great partner in the drug development process. ”
About
SENIOR INDUSTRY PHYSICIAN
Oncology | Hematology | Gastroenterology |…
Oncology | Hematology | Gastroenterology |…
Experience & Education
-
CymaBay Therapeutics
View William’s full experience
See their title, tenure and more.
or
Volunteer Experience
Publications
-
A phase I study of CR002, a fully-human monoclonal antibody against platelet-derived growth factor-D
Int J Clin Pharmacol Ther
-
Integrated acidity and rabeprazole pharmacology
Aliment Pharmacol Therapy
Part of an integrated development plan that led to the approval of rabeprazole (Aciphex®)
Other authors -
-
Single-Blind Study of the Effects of Intravenous Dolasetron Mesylate Versus Ondansetron on Electrocardiographic Parameters in Normal Volunteers
Jouenal of Cardiovascualr Pharamcology
Study was part of an integrated development plan to define the safety profile of dolasetron mesylate for FDA
Other authors -
-
Dose-Ranging Evaluation of the Serotonin Antagonist Dolasetron Mesylate (MDL 73,147EF) in Patients Receiving High-Dose Cisplatin
Journal of Clinical Oncology
Phase I dose escalating study of dolasetron mesylate (Anzemet®). Part of an integrated 10,000 patient study plan to support the safety and efficacy of dolasetron mesylate
Other authors -
-
Parenteral Control of Gastic Acid Hypersecretion in Patients with Zollinger-Ellison Syndrome
Dig Dis and Sciences
Publication of Data from a retrospective collection of data from the NIH. Part of approval history supporting the safety and efficacy of continuous infusion IV ranitidine.
Other authors -
-
Dose-Ranging Evaluation of the Serotonin Antagonist GR-C507/75 (GR 38032F- now Zofran®) When Used as an Anti-Emetic in Patients Receiving Anticancer Chemotherapy
Jounal of Clinical Oncology
I am not listed as an Author on this publication. It was an acknowledgement in an academic publication. This is actually the first clinical trial of ondansetron (Zofran®) under a compound name. this was the IND trial where I was the Glaxo Inc. Protocol Author.
Other authors -
Honors & Awards
-
American Gastroenterology National Student Research Prize
American Gastroenterology Association
Received for Submitted Paper on CCK Receptor Antagonists. Publication Hahne, et. al. Proc Natl Acad Sci 78:6305-6308, 1981
Organizations
-
American Society of Hematology
Member
- Present -
American Society of Clinical Oncology
Member
- Present
Recommendations received
5 people have recommended William
Join now to viewOther similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More